About this trial
Last updated 7 years ago
Study ID
ASPHINA 509-BER-401-17
Status
Terminated
Type
Interventional
Phase
N/A
Placebo
No
Accepting
All
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 7 years ago
What is this trial about?
Clinical safety and efficacy of CT ASPHINA 509 IOLs after implantation
What are the participation requirements?
Inclusion Criteria
- Patients of any gender
- Assured follow-up examinations
- Biometry measurement preferably compatible with the IOLMaster evaluation;
- IOL implanted into the capsular bag with IOL model CT ASPHINA 409MP (UVE material) in one eye with at least 12 months follow up at the time of the postop visit
- Patients who had uncomplicated (no peroperative complication) agedrelated cataract surgery in a healthy eye (beside clinically significant cataract)
Exclusion Criteria
- • BCVA not available preoperatively or better than 0.3 logMAR pre-op
- Patients unable to meet the limitations of the protocol or likely of noncooperation during the trial
- Patients whose freedom is impaired by administrative or legal order
- Concurrent participation in another drug or device investigation